Eli Lilly developed the diabetes and obesity drug Mounjaro and became a major high-value listed company.
Eli Lilly markets tirzepatide under the brand name Mounjaro for type 2 diabetes and Zepbound for chronic weight management in the United States. Tirzepatide acts on two hormone pathways, GIP and GLP-1, which helped make it a major pharmaceutical product and increased investor attention toward the company.
The company was founded in 1876 by Colonel Eli Lilly in Indianapolis. Its earlier medicines included insulin products and the antidepressant Prozac. Pharmaceutical market capitalizations can change sharply when clinical results, regulatory decisions, or sales forecasts alter expectations.
Mounjaro and Zepbound are brand names for the same active ingredient, tirzepatide, but their approved uses and labeling differ. That distinction is a frequent source of confusion.